[OncoHost in PR Newswire] OncoHost announces interim results from PROPHETIC trial, multicenter assessment of NSCLC patient response to immunotherapy

Source Node: 1587657

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced results from its ongoing multicenter clinical trial, PROPHETIC. These interim results confirm that through proteomic analysis of just one blood test before treatment, OncoHost’s AI platform, PROphet®, can predict response to cancer treatment for non-small cell lung cancer (NSCLC) patients with remarkably high accuracy at three months, six months and one year.

Read more here.

Source: https://blog.ourcrowd.com/oncohost-announces-interim-results-from-prophetic-trial-multicenter-assessment-of-nsclc-patient-response-to-immunotherapy/

Time Stamp:

More from OurCrowd Blog